(Q38736126)

6 September 2017

title

Immunotherapy for small-cell lung cancer: emerging evidence (English)

1 reference

6 September 2017

1 reference

1 reference

Martin Reck

1

1 reference

6 September 2017

David Heigener

series ordinal

2

1 reference

6 September 2017

Niels Reinmuth

series ordinal

3

1 reference

6 September 2017

language of work or name

English

0 references

publication date

17 February 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

12

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

931-943

1 reference

Small cell lung cancer: where do we go from here?

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Relapsed small cell lung cancer: treatment options and latest developments

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Treatment options for small cell lung cancer - do we have more choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Cancer immunotherapy comes of age

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Histologic assessment of tumor-associated CD45(+) cell numbers is an independent predictor of prognosis in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Immunomodifiers in combination with conventional chemotherapy in small cell lung cancer: a phase II, randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Regulatory T cells in paraneoplastic neurological syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON-2015-0012

21 January 2018

Identifiers

DOI

10.2217/FON-2015-0012

1 reference

6 September 2017

1 reference